Explore chapters and articles related to this topic
Nutritional Strategies for Wound Healing in Diabetic Patients
Published in Jeffrey I. Mechanick, Elise M. Brett, Nutritional Strategies for the Diabetic & Prediabetic Patient, 2006
Neal G. Breit, Jeffrey I. Mechanick
Copper nutriture is related to ultimate scar strength and resistance. In animals, copper is released early in the tissue healing process with a measurable rise in serum levels [158]. Copper neutralizes tolmetin (a nonselective cyclooxygenase-2 inhibitor)-induced impairments on the tensile strength of newly healed wounds [259]. In keratinocyte monolayer cultures, copper gluconate upregulates inte-grin-α2, -α6 and -β1 gene expression in differentiated keratinocytes during the final re-epithelialization phase of wound healing [160]. Copper also has a role in VEGF-mediated angiogenesis, extracellular matrix remodeling, and dermal wound contracture and closure [161]. Potential adverse effects of copper supplementation include hemolytic anemia, jaundice, nausea, vomiting, abdominal pain, headache, weakness, diarrhea, hepatopathy, and hemochromatosis. There are no clinical data on the routine use of copper supplementation for wound healing in diabetic patients (evidence level 4, grade D).
The treatment of hepatocellular carcinoma with SP94 modified asymmetrical bilayer lipid-encapsulated Cu(DDC)2 nanoparticles facilitating Cu accumulation in the tumor
Published in Expert Opinion on Drug Delivery, 2023
Hao Liu, Yihan Kong, Xue Liang, Zixu Liu, Xueting Guo, Bing Yang, Tian Yin, Haibing He, Jingxin Gou, Yu Zhang, Xing Tang
In this study, the vital role played by copper ions in DSF/DDC-based cancer therapy was examined. Although pre-enriched intracellular copper ions increased the cancer cell killing activity of DSF/DDC in vitro, no satisfactory inhibition effect on tumor growth was found in vivo. Furthermore, oral administration of copper gluconate was hard to increase copper levels in plasma and tumor. The strict Cu regulatory system inhibited the accumulation of the copper ion and led to a more rapid efflux of copper ions when much more copper ions were given, thus resulting in the diminished anti-cancer activity of DSF/DDC. However, complexing with DSF/DDC to prepare Cu(DDC)2 was proven to avoid the efflux of copper ions to increase the copper level in tumor tissues and more significantly inhibit tumor growth. Thus, the direct delivery of Cu(DDC)2 is more effective in achieving the antitumor effect of DSF/DDC in combination with copper ions. Furthermore, SP94 modified asymmetrical bilayer lipid shell was well produced to encapsulate Cu(DDC)2 nanoparticles. The novel SP94 modified asymmetrical bilayer lipid-encapsulated Cu(DDC)2 nanoparticles are capable of actively and efficiently delivering the therapeutic agent of Cu(DDC)2 to the site of tumor tissue for high therapy efficiency to refractory hepatocellular carcinoma.